Price$5.90+0.01 (+0.17%)
01:30 PM07:45 PM
News · 26 weeks60-22%
2025-10-262026-04-19
Mix3490d
- Insider18(53%)
- SEC Filings8(24%)
- Other7(21%)
- Offering1(3%)
Latest news
25 items- SECSEC Form PRE 14A filed by Annexon Inc.PRE 14A - Annexon, Inc. (0001528115) (Filer)
- INSIDERSEC Form 4 filed by Carson William H.4 - Annexon, Inc. (0001528115) (Issuer)
- PRAnnexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceBRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Ab
- SECSEC Form S-3ASR filed by Annexon Inc.S-3ASR - Annexon, Inc. (0001528115) (Filer)
- SECSEC Form 10-K filed by Annexon Inc.10-K - Annexon, Inc. (0001528115) (Filer)
- SECAnnexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
- PRAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive employee received an option to purchase 20,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $5.66, which was t
- INSIDERDirector Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard sold $32,004 worth of shares (5,894 units at $5.43), decreasing direct ownership by 3% to 180,093 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF FINANCIAL OFFICER Lew Jennifer sold $30,162 worth of shares (5,565 units at $5.42), decreasing direct ownership by 3% to 170,700 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF BUSINESS OFFICER Overdorf Michael sold $23,517 worth of shares (4,339 units at $5.42), decreasing direct ownership by 2% to 182,625 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Dananberg Jamie sold $31,603 worth of shares (5,820 units at $5.43), decreasing direct ownership by 4% to 123,582 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF INNOVATION OFFICER Yednock Ted sold $30,168 worth of shares (5,566 units at $5.42), decreasing direct ownership by 3% to 154,161 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- SECSEC Form 144 filed by Annexon Inc.144 - Annexon, Inc. (0001528115) (Subject)
- PRAnnexon Biosciences to Present at the TD Cowen 46th Annual Health Care ConferenceBRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon
- INSIDERSEC Form 4 filed by PRESIDENT AND CEO Love Douglas4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Dananberg Jamie was granted 56,250 shares, increasing direct ownership by 77% to 129,402 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF BUSINESS OFFICER Overdorf Michael was granted 62,500 shares, increasing direct ownership by 50% to 186,964 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard was granted 62,500 shares, increasing direct ownership by 51% to 185,987 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF INNOVATION OFFICER Yednock Ted was granted 62,500 shares, increasing direct ownership by 64% to 159,727 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF FINANCIAL OFFICER Lew Jennifer was granted 62,500 shares, increasing direct ownership by 55% to 176,265 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDEREVP & CHIEF FINANCIAL OFFICER Lew Jennifer sold $40,119 worth of shares (7,851 units at $5.11), decreasing direct ownership by 6% to 113,765 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Dananberg Jamie sold $26,979 worth of shares (5,290 units at $5.10), decreasing direct ownership by 7% to 73,152 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)